Abiomed restates three years' financial results
This article was originally published in Clinica
Implantable replacement heart manufacturer Abiomed is restating its financial results for the past three years in order to reflect modifications to its accounting methods. The Danvers, Massachusetts-based company says that its overall capital resources are not affected by the changes, which relate to the timing of how it recorded some revenues.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.